公开(公告)号：US12090227B2

公开(公告)日：2024-09-17

申请号：US18526168

申请日：2023-12-01

申请人： Jiangnan University ,  Standard Foods (China) Co., Ltd ,  Le Bonta Wellness Co., Ltd

发明人： Peng Zhou ,  Changshu Liu ,  Yaowei Liu ,  Tao Yang ,  Yan Zheng ,  Jianguo Liu ,  Kexin Li ,  Shuyan Lu

IPC分类号： A61K9/00 ,  A61K9/107 ,  A61K31/7028 ,  A61K47/26 ,  A61K47/42 ,  A61K47/44

CPC分类号： A61K9/1075 ,  A61K31/7028 ,  A61K47/26 ,  A61K47/42 ,  A61K47/44

摘要： The present disclosure relates to a method to improve the encapsulation efficiency and physicochemical stability of ginsenosides Rg3 and CK nano-emulsion, belonging to the field of functional emulsions. The method to improve the encapsulation efficiency and physicochemical stability of ginsenosides Rg3 and CK nano-emulsion, includes the following steps: (1) WPI, Tween 80 and water were mixed evenly according to the amount ratio of 0.5 g:0.5-0.7 g:50 mL to obtain the aqueous phase; (2) Mixing a saponin extract containing the minor ginsenosides Rg3 and CK with edible oil evenly to obtain the oil phase; (3) Mixing the aqueous phase with the oil phase, carrying out shearing dispersion to obtain coarse emulsion, and then allowing the coarse emulsion to be subjected to microfluidization homogenization to obtain an oil-in-water nano-emulsion containing the minor ginsenosides Rg3 and CK. The nano-emulsion of the disclosure has a high encapsulation efficiency of Rg3 and CK, good physicochemical stability during storage, freeze-thaw cycles, heating, and other industrial treatments, which could be used to improve the bioavailability of minor ginsenoside Rg3 and CK.

公开(公告)号：US12090139B2

公开(公告)日：2024-09-17

申请号：US17750354

申请日：2022-05-22

申请人： TONIX MEDICINES, INC.

发明人： Rajesh Gandhi ,  Sreekanth Manikonda ,  Arun Jana ,  Sameer Shrinivas Kunte

IPC分类号： A61K31/4045 ,  A61K9/00 ,  A61K31/40 ,  A61K31/404 ,  A61K31/70 ,  A61K31/7028 ,  A61K45/06 ,  A61K47/26

CPC分类号： A61K31/4045 ,  A61K9/0043 ,  A61K31/40 ,  A61K31/404 ,  A61K31/70 ,  A61K31/7028 ,  A61K45/06 ,  A61K47/26 ,  A61K31/404 ,  A61K2300/00 ,  A61K31/7028 ,  A61K2300/00

摘要： The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described.
The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

公开(公告)号：US20240299432A1

公开(公告)日：2024-09-12

申请号：US18609604

申请日：2024-03-19

申请人： Massachusetts Eye and Ear Infirmary

发明人： Zheng-Yi Chen ,  Wenyan Li ,  Yi-Zhou Quan

IPC分类号： A61K31/7028 ,  A61K31/19 ,  A61K31/365 ,  A61K45/06

CPC分类号： A61K31/7028 ,  A61K31/19 ,  A61K31/365 ,  A61K45/06

摘要： Compositions for regeneration of inner cells and for treating hearing loss comprise at least one modulator of mechanistic target of rapamycin (mTOR) sufficient to induce reprogramming proliferation and regeneration of inner ear cells. The composition include, in some instances, an effective amount of one or more phosphatase and tensin homolog (PTEN) inhibitors, MYC/NOTCH modulators, Atonal Homolog 1 (Atoh1) modulators or combinations thereof.

公开(公告)号：US20240277740A1

公开(公告)日：2024-08-22

申请号：US17998822

申请日：2021-05-12

申请人： Viratides, LLC

发明人： Jason R. Bond

IPC分类号： A61K31/7028 ,  A61K9/127 ,  A61P31/14 ,  A61P31/16 ,  A61P31/22

CPC分类号： A61K31/7028 ,  A61K9/1272 ,  A61P31/14 ,  A61P31/16 ,  A61P31/22

摘要： The present invention provides compositions, systems, kits, and methods for treating a subject with a known or unknown enveloped or non-enveloped viral infection (e.g., an unknown virus, RSV, ADV, SARS-CoV2, CHKV, DENV, HSV-1, HSV-2, EBOV, MARV, ZIKV, or a weaponized virus) by administering or providing a composition comprising a lipid agent selected from: a sulfatide, a sulfatide analog, a ceramide, a lipid moiety comprising a ceramide, a sulfoglycolipid, a sulfogalactolipid, a glycosphingolipid, a seminolipid, or a sphingomyelin. In some embodiments, the compositions reduce lung or systemic inflammation in the subject and/or inhibit viral infection. In certain embodiments, the compositions herein are employed to stop a natural pandemic or a biological attack (e.g., with new or weaponized viruses).

公开(公告)号：US12064471B2

公开(公告)日：2024-08-20

申请号：US17178664

申请日：2021-02-18

申请人： NUTRAMAX LABORATORIES, INC.

发明人： Brian Cornblatt ,  Grace Cornblatt ,  Anton Bzhelyansky ,  Robert Henderson

IPC分类号： A23L33/105 ,  A61K9/00 ,  A61K9/14 ,  A61K9/28 ,  A61K31/19 ,  A61K31/194 ,  A61K31/26 ,  A61K31/357 ,  A61K31/375 ,  A61K31/7028 ,  A61K31/716 ,  A61K33/06 ,  A61K36/00 ,  A61K36/06 ,  A61K36/07 ,  A61K36/28 ,  A61K36/31 ,  A61K38/47 ,  A61K45/06 ,  A61K47/42 ,  A61P3/06

CPC分类号： A61K38/47 ,  A23L33/105 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/28 ,  A61K31/19 ,  A61K31/194 ,  A61K31/26 ,  A61K31/357 ,  A61K31/375 ,  A61K31/7028 ,  A61K31/716 ,  A61K33/06 ,  A61K36/06 ,  A61K36/07 ,  A61K36/28 ,  A61K36/31 ,  A61K45/06 ,  A61K47/42 ,  A61P3/06 ,  C12Y302/01147 ,  A23V2002/00 ,  A61K36/31 ,  A61K2300/00 ,  A61K33/06 ,  A61K2300/00 ,  A61K31/7028 ,  A61K2300/00 ,  A61K38/47 ,  A61K2300/00 ,  A61K31/375 ,  A61K2300/00 ,  A61K31/26 ,  A61K2300/00 ,  A61K36/28 ,  A61K2300/00 ,  A61K36/06 ,  A61K2300/00 ,  A61K36/07 ,  A61K2300/00

摘要： The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a β-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.

公开(公告)号：US20240238186A1

公开(公告)日：2024-07-18

申请号：US18557661

申请日：2022-04-29

申请人： CarboCode S.A.

发明人： Bruce McConnell ,  Cornelia Pyko ,  Feryel Adam

IPC分类号： A61K8/68 ,  A61K31/164 ,  A61K31/7028 ,  A61Q17/00 ,  A61Q19/00 ,  A61Q19/08

CPC分类号： A61K8/68 ,  A61K31/164 ,  A61K31/7028 ,  A61Q17/00 ,  A61Q19/007 ,  A61Q19/08

摘要： The present invention relates to a topical composition comprising one or more compounds of formula (I), wherein X is hydrogen or a glycosyl moiety, the carbon-carbon bond noted is a double or a single bond, R1 is an alkyl chain having 10-20 carbon atoms, R2 is hydrogen or a substituted or unsubstituted acyl having 16-34 carbon atoms, R3 is hydrogen when the carbon-carbon bond noted is a double or a single bond, and R3 is —OH when the carbon-carbon bond noted is a single bond, R4 is hydrogen when the carbon-carbon bond noted is a double or a single bond, and R4 is hydrogen or —OH when the carbon-carbon bond noted is a double bond, said composition is characterized in that at least one of the one or more compounds of formula (I) has a lactosyl moiety or a glucosyl moiety in the position X.

公开(公告)号：US20240226000A9

公开(公告)日：2024-07-11

申请号：US18351192

申请日：2023-07-12

申请人： Dyve Biosciences, Inc.

发明人： Nathan FITZSIMMONS ,  Ryan BEAL ,  Charles A. HARBERT ,  Audrene RICE ,  Brandon SAND ,  Parshva KOTHARY ,  Bruce SAND

IPC分类号： A61K9/00 ,  A61K9/06 ,  A61K31/196 ,  A61K31/4015 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/436 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/522 ,  A61K31/546 ,  A61K31/573 ,  A61K31/575 ,  A61K31/65 ,  A61K31/7028 ,  A61K31/7052 ,  A61K31/7064 ,  A61K33/26 ,  A61K38/07 ,  A61K38/14 ,  A61K38/48 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/24

CPC分类号： A61K9/0014 ,  A61K9/06 ,  A61K31/196 ,  A61K31/4015 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/436 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/522 ,  A61K31/546 ,  A61K31/573 ,  A61K31/575 ,  A61K31/65 ,  A61K31/7028 ,  A61K31/7052 ,  A61K31/7064 ,  A61K33/26 ,  A61K38/07 ,  A61K38/14 ,  A61K38/4893 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/24 ,  C12Y304/24069

摘要： The present disclosure relates to a formulations and methods for transdermal delivery of a medicament through the skin of a subject. In aspects, the formulation comprises a therapeutically effective amount of a medicament and a penetrant portion in which the penetrant portion comprises: a phospholipid, a fatty acid ester formed from a low molecular weight alcohol, and a long-chain fatty acids. In some embodiments, the penetrant portion further comprises one or more of a viscosity-improving agent, a penetration enhancer, and an emulsifier.

公开(公告)号：US20240180941A1

公开(公告)日：2024-06-06

申请号：US18495450

申请日：2023-10-26

申请人： Flagship Pioneering Innovations V, Inc.

发明人： Steven John TAYLOR ,  John Robert PROUDFOOT ,  Mi-Jeong KIM ,  Kathleen NUDEL ,  Timothy F. BRIGGS ,  Afrand KAMALI SARVESTANI ,  Leonard BUCKBINDER ,  Bernard LANTER ,  Ferdinand Edward MASSARI ,  Koji YASUDA ,  Spencer Cory PECK ,  Cheri SNEDEKER ,  Diana LE ,  Jessica ALEXANDER ,  Anna LIANG ,  Dinara GUNASEKERA ,  David Arthur BERRY ,  John Patrick CASEY, JR.

IPC分类号： A61K31/7028 ,  A61K45/06 ,  A61P3/10

CPC分类号： A61K31/7028 ,  A61K45/06 ,  A61P3/10

摘要： Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.

公开(公告)号：US11969436B2

公开(公告)日：2024-04-30

申请号：US16768180

申请日：2018-11-29

申请人： Kao Corporation

发明人： Rie Ninomiya ,  Takafumi Nishijima ,  Noriko Sato

IPC分类号： A61K31/7028 ,  A61K31/26 ,  A61K36/31 ,  A61P17/04 ,  A61Q19/00 ,  C12Q1/44 ,  G01N33/50

CPC分类号： A61K31/7028 ,  A61K31/26 ,  A61K36/31 ,  A61P17/04 ,  C12Q1/44 ,  G01N33/5023

摘要： To provide a method for evaluating or selecting an agent for reducing sensory irritation, which reduces sensory irritation caused by parabens, and an agent for reducing sensory irritation, which reduces sensory irritation caused by parabens. A method for evaluating or selecting an agent for reducing sensory irritation caused by parabens, comprising the following steps (1) to (3): (1) a step of contacting cells capable of expressing CES1 with a test substance; (2) a step of measuring expression of CES1 in the cells; (3) a step of evaluating a test substance which promotes expression of CES1 as an agent for reducing sensory irritation caused by parabens based on the results measured in (2).

公开(公告)号：US20240115618A1

公开(公告)日：2024-04-11

申请号：US18481041

申请日：2023-10-04

申请人： Wayne Gregory Kimpton ,  Simon Reeves Bailey ,  Silviu Itescu ,  Peter Ghosh

发明人： Wayne Gregory Kimpton ,  Simon Reeves Bailey ,  Silviu Itescu ,  Peter Ghosh

IPC分类号： A61K35/28 ,  A61K9/00 ,  A61K31/7028 ,  C12N5/0775

CPC分类号： A61K35/28 ,  A61K9/0019 ,  A61K31/7028 ,  C12N5/0663

摘要： The present disclosure provides a method for treating or preventing endothelial dysfunction in a subject, the method comprising systemically administering to the subject a population of population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.